"If full presentation of the data at the ISTH reassures ... Roche is hoping to make some serious inroads with emicizumab. Roche’s Genentech unit already announced preliminary results showing ...

Roche's haemophilia drug, emicizumab, has succeeded in a late-stage trial in haemophilia A, as the Swiss company hopes to take on rivals from Novo Nordisk and Shire. Emicizumab was developed by ...

Roche has reported a 7% increase in full-year ... and the haemophilia treatment Hemlibra (emicizumab-kxwh). Combined, these products pulled in CHF 16.9bn ($18.6bn), marking a CHF 3.3bn ($3.6bn ...